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influence treatment outcome or treatment toxicity. Furthermore, no 
enhanced RBE was found for FFF compared to FF photon beams. 
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Purpose/Objective: Radiotherapy to collateral structures such as the 
carotid artery leads to atherosclerosis and increased stroke risk. 
Arterial thickening is a precursor to atherosclerosis. Carotid intima-
medial thickness (CIMT), a measure of arterial thickening, is a 
validated surrogate for prediction of cardio- and cerebrovascular 
events. Its application in irradiated arteries as a measure of 
accelerated atherosclerosis has shown variable results. This study 
investigates CIMT as an early marker of radiation-induced damage in 
head and neck cancer patients. 
Materials and Methods: Patients with head and neck cancer treated 
with a wedged-pair and matched neck technique or hemi-neck 
radiotherapy (unirradiated (unirr) side as control) at least 2 years 
previously were included. Patients had been prescribed a dose of at 
least 50 Gy to the neck. CIMT was measured on B-mode ultrasound 
using semi-automated detection software. Measurements were taken 
from the far wall in 4 arterial segments: proximal- (prox), mid-, distal 
(dist) common carotid artery (CCA), and bifurcation and were 
compared to corresponding segments in the unirr artery. CIMT 
measurements >75th percentile of a reference normal population were 
considered abnormal and at increased cardiovascular risk. 
Results: 24 patients (16 males) with a median age of 58 yrs 
(interquartile range (IQR) 49.2 – 64.2) were included. The mean 
maximum dose to the irradiated (irr) artery was 61.2 Gy (IQR 52.6 – 
61.8) and 1.1 Gy (IQR 1.0 – 1.8 Gy) to the unirr carotid artery. Mean 
CIMT was significantly greater in irr carotid arteries compared to unirr 
arteries: mid-CCA (0.75mm ± 0.2 (irr) vs 0.64mm ± 0.12 (unirr) (P = 
0.0057), distal CCA (0.79mm ± 0.24 (irr) vs 0.64mm ± 0.14 (unirr) (P = 
0.005), and bifurcation (0.85mm ± 0.28 (irr) vs 0.7mm ± 0.17 (unirr) (P 
= 0.0231). For the irr prox CCA, 23/24 (95.8%) had a CIMT > 75th 
percentile vs 16/24 (66.7%) for unirr prox CCA. For irr mid CCA, 20/24 
(83.3%) had CIMT >75th percentile vs 15/24 (62.5%) for unirr mid CCA. 
21/24 (87.5%) of irr dist CCA CIMT was >75th percentile vs 11/24 (45.8) 
for unirr dist CCA. For irr bifurcation, 15/21 (71.4%) had a CIMT >75th 
percentile vs 11.24 (45.8%) for unirr bifurcation. 
Conclusions: CIMT is increased in irr carotid arteries, suggesting this 
may be a useful marker of radiation-induced carotid atherosclerosis. 
The proximal CCA appears to be less sensitive to radiation-induced 
damage. 
   
PD-0187   
Hyperbaric oxygen therapy for late adverse events after particle 
radiotherapy 
Y. Niwa1, M. Murakami2, Y. Demizu3, O. Fujii3, K. Terashima3, M. 
Mima3, Y. Ooe4, N. Fuwa5, N. Kamikonya1, S. Hirota1 
1Hyogo College of Medicine, Radiology, Hyogo, Japan  
2Dokkyo Medical University, Radiation Oncology Center, Tochigi, 
Japan  
3Hyogo Ion Beam Medical Center, Radiology, Hyogo, Japan  
4Uegahara Hospital, Director, Hyogo, Japan  
5Hyogo Ion Beam Medical Center, Director, Hyogo, Japan  
 
Purpose/Objective: This is the first report on the application and 
outcomes of hyperbaricoxygen therapy (HBO) for late adverse events 
which developed after proton or carbon-ionbeam radiation therapy. 
Materials and Methods: Between April 2008 and May 2012, 40 patients 
underwent HBO for late adverse events (105 episodes of 8 events) 
which developed more than 5 months after particle radiotherapy. 
There were 24 male and 16 female patients aged 15-83 years (median: 
67 years), and the performance state (PS) at the initiation of HBO 
was: PS0:PS1:PS2:PS3= 0:24:13:3. The primary diseases treated with 
particle radiotherapy were head-and-neck tumor in 23 patients, 
prostate cancer in 8, bone soft tissue tumor in 5, liver cancer in 4, 
and lung metastasis in 1. The late adverse events treated with HBO 
were classified into 8 events using CTC-AEver. 4.0. HBO was 
performed 3 times or more weekly, as a rule. The HBO chamber was 
compressed with 100% oxygen to 2.0 ATA inside, and the duration of 
treatment (pressure-keeping time) was 60 minutes. Responder of HBO 
was defined as a case of improvement in CTC-AE score. 
 
 
Results:  
  
HBO was initiated 5-64 months (median: 19 months) after particle 
radiotherapy. The total number of HBO was 4-120 (median: 29). Table 
shows grading score of late adverse events before and after HBO. 
Response rate (number of responder/total cases) of 8 events was: 
hematuria, 100% (4/4); rectal bleeding, 67% (4/6); pain, 56% (18/32); 
central nervous necrosis, 50% (2/4); mucosalulcer or fistula, 36% 
(8/22); mandibular bone necrosis, 28% (5/18); trismus, 15% (2/13); 
and skin ulcer, 0% (0/9). Total response rate was 40% (43/105). The 
average number of HBO was significantly higher in responder 
(69±48.9) than in non-responder (44±27.9) groups (p=.001). Adverse 
events due to ABO were minimal. Otitis media (non-infectious) 
occurred in 14 patients (35%) (Grade 1in 12 (30%), Grade 2 in 1 (2.5%) 
and Grade3 in 1 (2.5%)). TIA, diarrhea, bronchitis, cerebral infarction 
and sinusitis occurred in each one patient, however these events were 
transient and HBO did not be discontinued. 
Conclusions: HBO was effective for late radiation disorders after 
particle radiotherapy especially in hematuria, rectal bleeding, pain, 
and central nervous necrosis. Total response rate was 40% (43/105). It 
was suggested that many times (69±48.9) applications of HBO are 
necessary to obtain an effect.  
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Purpose/Objective: Numerous studies investigate the normal tissue 
dose-response relation. However, limited numbers of patients per 
study and the low incidence of toxicities render the relation 
uncertain. The aim of this study is to apply a statistical bootstrap 
analysis to evaluate the uncertainty in the predicted dose-response 
due to sampling variability. 
Materials and Methods: Two clinical endpoints were considered: 
myelopathy of the cervical spinal cord and pneumonitis. Data was 
taken from the recently published QUANTEC review. In order to 
evaluate the uncertainty in the clinical data, a Monte Carlo-based 
bootstrap analysis was applied. Ten thousand bootstrap replicates of 
the original dataset were produced by random sampling with 
replacement. This simulates alternative outcomes at each dose in a 
different sample of patients of the same size from the same 
population. The analysis requires only the dose, the number of 
patients, and the number of occurrences of the studied endpoint. The 
dose reported in the QUANTEC review was used: the equivalent dose 
given in 2-Gy fractions (EQD2) for the spinal cord, and the mean dose 
for the lung. Two dose-response models, a Poisson-based model and 
the Lyman model, were fitted to each bootstrap replicate using 
maximum likelihood. 
Results: The bootstrap analysis generates a family of curves 
representing the range of plausible dose-response relations. The 95% 
confidence intervals of the curve families for the two models overlap 
for doses included in the clinical study, but diverge beyond that. For 
higher doses, the Lyman model indicates a steeper slope than does 
the Poisson-based model. The bootstrap distributions of the model 
parameters D50 and y (m) indicate negative (positive) correlation. For 
both data sets, the likelihood of the observed data was higher for the 
Lyman model. This result was robust over the bootstrap analysis with 
higher likelihood of the Lyman model for over 90% of the bootstrap 
replicates, in both data sets. 
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Conclusions: The bootstrap provides a statistical analysis of the 
uncertainty in the estimated dose-response relation. It suggests likely 
values of D50 and y (m), their confidence intervals, and how they 
interrelate for each model. Finally, it can be used to evaluate to what 
extent data supports one model over another. Both data sets 
considered here provided fairly strong support to the Lyman model 
over the Poisson-based model.  
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Purpose/Objective: Radiation-induced hypothyroidism (RHT) is a 
frequent side effect after therapeutic irradiation of the cervical 
region and it has been described in patients undergoing radiation 
therapy (RT) for different neoplasms such as lymphoma, head-and-
neck cancer and breast cancer. Purpose of this work is to develop 
multivariate normal tissue complication probability (NTCP) models for 
RHT and to compare them with already existing NTCP models for RHT. 
Materials and Methods: Fifty-three patients treated at our 
department with sequential chemo-radiotherapy for Hodgkin’s 
lymphoma (HL) were retrospectively reviewed for RHT events. Clinical 
information along with thyroid gland dose distribution parameters 
were collected and their correlation to RHT was analyzed by 
Spearman’s rank correlation coefficient (Rs). Multivariate logistic 
regression method using resampling methods (bootstrapping) was 
applied to select model order and parameters for NTCP modeling. 
Model performance was evaluated through the area under the receiver 
operating characteristic curve (AUC). Models were tested against 
external published data on RHT and compared with other published 
NTCP models. 
Results: When we express the thyroid volume exceeding XGy as a 
percentage (Vx(%)), a two-variable NTCP model including V30(%) and 
gender (female=0, male=1) was suggested as the optimal predictive 
model for RHT (Rs= 0.615, p<0.001. AUC= 0.87). Conversely, when 
absolute thyroid volume exceeding X Gy (Vx(cc)) was analyzed, an 
NTCP model based on 3 variables including V30(cc), thyroid gland 
volume (VT) and gender was selected as the most predictive model 
(Rs=0.630, p<0.001, AUC= 0.85).The three-variable model have a 
better performance (AUC= 0.914, 95%CI0.760-0.984) when tested on 
an external cohort characterized by large inter-individuals variation in 
thyroid volumes. The risk of RHT is given by:  
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The behavior of the NTCP for male and female is represented in figure 
1. 
A comparable performance was found between our model and that 
proposed in the literature based on thyroid gland mean dose and 
volume (p= 0.264). 
 
 
 
Figure 1 
 
 
Conclusions: The absolute volume of thyroid gland exceeding 30 Gy in 
combination with thyroid gland volume and gender provide an NTCP 
model for RHT with improved prediction capability not only within our 
patient population but also on an external cohort. 
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Purpose/Objective: Radiation-induced lung damage (RILD) is one 
ofthe most important dose-limiting toxicities in the treatment of lung 
cancer patients. Prediction models are still unsatisfactory, partly 
because clinical toxicity endpoints such as dyspnea are influenced by 
many parameters and difficult to quantify objectively. Furthermore, 
interactions between drugs and radiotherapy (RT) are difficult to 
assess. We therefore evaluated RILD more objectively, quantitatively 
and on a continuous scale measuring the regional lung tissue density 
changes per voxel. 
Materials and Methods: Multiple treatment regimens of lung cancer 
(both SCLC and NSCLC) were retrospectively analysed: radiotherapy 
alone, sequential and concurrent chemo-radiotherapy with or without 
the addition of the targeted agent cetuximab. Follow-up CT scans up 
to 6 months (range, 2-6 months) after the end of treatment were co-
registered using deformable registration to baseline CT scans. CT 
density changes (expressed in Hounsfield Units) in the lungs were 
correlated to the RT dose delivered in every part (i.e. voxel) of the 
lungs. 
Results: CT scans from 119 lung cancer patients were studied. 
Patients received a mean dose of 60 Gy (range 45-80 Gy) to the 
tumor. For the different treatment modalities: patients treated only 
with RT (N=19), sequential chemo-RT (N=30), concurrent chemo-RT 
(N=51), concurrent chemo–RT with cetuximab (N=19), the absolute 
increase in HU for voxels receiving between 40 and 50 Gy was 27 ±26, 
38 ± 45, 29 ± 38, and 54 ± 33 HU, respectively. Furthermore, dose-
response curves were linear in the dose-region between 0 and 80 Gy 
with a slope expressed as a lung density increase per dose (HU/Gy), of 
0.7 ± 0.7, 1.2± 1.2, 1.1 ± 1.2, and 1.6 ± 1.0 HU/Gy. Hence, the dose-
response curve for the group treated with the targeted agent 
cetuximab showed more susceptibility for RILD (P < 0.03) compared to 
(chemo-) radiotherapy. 
Conclusions: CT density changes allow quantitative non-invasive 
assessment of lung toxicity, giving complementary information to 
standard used clinical endpoints. Patients receiving cetuximab showed 
a higher increase in HU and a significantly larger dose response 
compared with the patients not receiving cetuximab.  
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